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Ex vivo approach: transduction of fibroblasts with plasmid vectors (2001) 
 
 
 
 
 
 
 
 
 
 
In vivo approach: cell transduction with γ-retroviral vectors (2003) 
 
 
 
 
 
 
 
 
 
 
In vivo approach: cell transduction with HD-adenoviral vectors (2005) 
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In vivo approach: transduction of the liver with AAV2 (2006) 
 
 
 
 
 
 
 
 
 
 
In vivo approach: transduction of the liver AAV8 (2011) 
 
 
 
 
 
 
 
 
 
 
Ex vivo approach: transduction of HSCs with lentiviral vectors (2014) 
Hemophilia is a hereditary coagulation disorder caused by lack of a coagulation 
factor. Patients have frequent  bleeding that sometimes can cause death. The main 
forms of this disease are hemophilia A (deficiency of FVIII factor) and hemophilia B 
(deficiency of FIX factor). Both of them have an X-linked inheritance. 
 
The current treatment involves frequent intravenous injections of the clotting factor. 
But this approach has limitations (price, accessibility and development of inhibitors), 
so it’s important to develop a new treatment. This work presents gene therapy as an 
option to treat hemophilia. 
To understand the clinical and genetic characteristics of hemophilia as a disease, as 
well as current treatments available. 
 
To consolidate the concept of gene therapy and its technical characteristics. 
 
To determine the evolution of the field of gene therapy for hemophilia in the last 
years: from the early clinical trials to the present. 
 
To establish whether gene therapy is an appropriate and beneficial treatment for 
hemophilia: determine the clinical hardships of the gene therapy. 
As a basis for the development of this work, many information sources such as 
reviews, scientific papers, theses, books and official websites were consulted. All the 
information was verified and filtered to obtain a well structured study. Only those 
topics of greatest interest were selected. With all the gathered information, a written 
report and a poster were made. 
Phase I Clinical trial 
Hemophilia A 
 
Results: 
 
-Safe and well tolerated. 
-Modest expression. 
-Transient effect. 
 
 
 
 
• Roth DA et al. (2001). The New England Journal of Medicine, 344(23):1735–1742. 
• Powell JS et al. (2003). Blood, 102(6):2038–2045. 
• White GC et al. Gene therapy for haemophilia A. Textbook of Haemophilia. 2nd ed. Hoboken, NJ; 2005. 
• Manno CS et al. (2003). Blood, 101(8):2963–2972. 
• Manno CS et al. (2006). Nat Med, 12(3):342–347. 
• Nathwani, A. C. et al. (2011). The New England Journal of Medicine, 365(25), 2357–2365.  
• Shi, Q. et al. (2014). Blood, 123(3), 395–403. doi:10.1182/blood-2013-08-520478 
 
 
 
-The work presented in this poster is a general view about the evolution of gene therapy 
strategies to treat hemophilia. There exist multiple preclinical and clinical trials for this 
disease, but this work is centered in the most relevant ones. 
 
-In conclusion, in this work all the objectives were met. A general knowledge about clinical 
and genetic characteristics, and treatments of hemophilia was reached. With the 
information sources consulted it was possible to determine the evolution of the trials used 
since the beginning to the present, and the feasibility and appropriateness of gene therapy 
as a treatment for hemophilia. 
 
Phase I Clinical trial 
Hemophilia A 
 
Results: 
 
-Safe and well tolerated. 
-Low expression. 
-Transient effect. 
-Higher doses are 
needed. 
Phase I Clinical trial 
Hemophilia A 
 
Results: 
 
-Severe hepatotoxicity. 
-Discontinued. 
 
 
 
 
 
Phase I/II Clinical trial 
Hemophilia B 
 
Results: 
 
-Safe and well tolerated. 
-Modest expression. 
-Long term local effect. 
-Multiple injections. 
 
 
 
 
 
Phase I/II Clinical trial 
Hemophilia B 
 
Results: 
 
-Transient hepatotoxicity. 
-Modest expression. 
-Transient effect. 
-Immune destruction of 
transduced hepatocytes.  
 
 
 
 
 
Phase I/II Clinical trial 
Hemophilia B 
 
Results: 
 
-Hepatotoxicity: resolved 
with corticosteroids. 
-Modest expression. 
-Long term effect.  
 
 
 
 
 
Preclinical trial 
Hemophilia A 
 
Results: 
 
-Phenotype correction. 
-Modest expression. 
-Promising approach. 
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4- CHARACTARISTICS OF THE VECTORS 
 
 
 Currently the most promising approaches are the lentiviral and AAV vectors, based 
on the level of expression and immunogenicity. From now on the aim is to improve 
these vectors to obtain greater expression using lower doses to reduce the immune 
response. 
 
 The liver is a promising target tissue due to its ability to induce immune tolerance, 
its high secretory capacity and its aptitude to create the endogenous post-
translational modifications. 
 
 One of the bottlenecks of gene therapy is the vector production. 
 
 Gene therapy is a relatively new field so we have yet to see the long term effects. 
 7- DISCUSSION AND CONCLUSIONS  
 
 
